Examining PCSK9 Inhibitor Use in the Post-MI Patient: Evidence and Examples

CME : 1 + more
Start Date :  Jan 07, 2021End Date :  Jan 07, 2022

Organized by :   Medscape, LLC

Specialties :   Cardiology, Emergency Medicine

Fees Fee :   Starting From Free

Conference Summary

Examining PCSK9 Inhibitor Use in the Post-MI Patient: Evidence and Examples is organized by Medscape, LLC.

CME / ABIM MOC / CE Released: 1/7/2021
Valid for credit through: 1/7/2022

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Goal Statement:
The goal of this activity is to improve understanding of lipid-lowering guidelines and the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients at very high risk for cardiovascular (CV) events, including a potential role in post-myocardial infarction (MI) patients.

Upon completion of this activity, participants will:
• Have increased knowledge regarding the
○ Guideline recommendations for lipid lowering and CV risk reduction in post-MI patients
○ Safety and efficacy of PCSK9 inhibitors in post-MI patients
• Have greater competence related to
○ Individualization of lipid-lowering therapy in patients with acute coronary syndrome (ACS)

Credit Info

  • CME : 1
  • MOC : 1
Contact Us

Toll free Number

1(800) 826-2059



Chat Assistant

Live Chat